• Tuberculosis and Respiratory Diseases
• /
• 제48권5호
• /
• pp.794-801
• /
• 2000

약제 유발성 BOOP의 경우는 약을 중단하여도 증상과 방사선학적 소견이 호전되지 않을 수 있고 부신피질스테로이드를 사용한 후 뚜렷한 호전을 보일 수 있기 때문에 BOOP를 일으킬 수 있는 약제에 대한 인지가 진단과 치료에 중요하다. 저자들은 carbamazepine에 의한 BOOP 1예를 경험하였기에 보고하는 바이다.

• 대한임상약리학회:학술대회논문집
• /
• 대한임상약리학회 1996년도 정기총회 및 추계학술대회
• /
• pp.34-34
• /
• 1996

• Journal of Oral Medicine and Pain
• /
• 제34권2호
• /
• pp.207-216
• /
• 2009

2003년부터 2008년까지 경북대학교병원 구강내과를 내원한 삼차신경통 환자 90명의 임상 소견 및 약물 치료에 대한 결과를 분석하여 다음과 같은 결론을 얻었다. 1. 삼차신경통 환자는 40대 이상이 94.4%를 차지하였고 남녀비가 1:2.1로 여성에서 거의 2배 정도 호발하였다. 2. 삼차신경의 상악분지에 단독으로 이환된 경우가 51.1%로 가장 많았고 좌우비가 1:2.9로 우측에 더 자주 발생하였다. 3. 85명(94.4%)의 환자가 경북대학교병원 구강내과에 내원하기 전 삼차신경통을 치료하기 위해 다른 의료기관을 내원한 경험이 있었다. 3. 40명(44.4%)의 환자가 현재 치료 중인 전신질환을 가지고 있었다. 4. Carbamazepine 단독 투여로 69명(76.7%)의 환자가 효과를 나타내었으며 이 때 사용된 Carbamazepine의 일일 용량은 평균 402.9mg이었다. 반면에 16명(17.8%)의 환자는 Carbamazepine과 다른 약물을 복합 투여하여 효과를 나타내었고 사용된 Carbamazepine 일일 용량은 평균 618.8mg이었으며 가장 많이 사용된 병용 약물은 Baclofen이었다. 나머지 5명(5.6%)의 환자는 Carbamazepine으로 효과를 얻지 못했다. 5. Carbamazepine 단독 투여에 효과가 있었던 69명 중 39명은 내원 기간 동안 지속적인 효과를 나타내었으나 30명은 Carbamazepine에 대한 효과가 감소하였거나 부작용으로 인해 복합 투약을 시행하였거나 다른 약물로 교체 또는 신경외과로 의뢰하였다. 6. 54명(60%)의 환자에서 Carbamazepine 투여 후 현기증, 졸음, 오심, 혈구 감소, 피부 발진 등의 부작용이 발생하였으나 대부분 그 정도가 미약하거나 일시적이었고 11명의 환자가 부작용으로 인해 Carbaamzepien 투약을 중단하였다.

• The Korean Journal of Physiology and Pharmacology
• /
• 제17권6호
• /
• pp.485-491
• /
• 2013

The present study was designed to investigate the putative effect of neurosteroid modulation on global ischaemia-reperfusion-induced cerebral injury in mice. Bilateral carotid artery occlusion followed by reperfusion, produced a significant rise in cerebral infarct size along with impairment of grip strength and motor coordination in Swiss albino mice. Administration of carbamazepine (16 mg/kg, i.p.) before global cerebral ischaemia significantly attenuated cerebral infarct size and improved the motor performance. However, administration of indomethacin (100 mg/kg, i.p.) attenuated the neuroprotective effect of carbamazepine. Mexiletine (50 mg/kg, i.p.) did not produce significant neuroprotective effect. It may be concluded that the neuroprotective effect of carbamazepine may be due to increase in synthesis of neurosteroids perhaps by activating enzyme ($3{\alpha}$ HSD) as indomethacin attenuated the neuroprotective effect of carbamazepine. The sodium channel blocking effect of carbamazepine may not be involved in neuroprotection as mexiletine, a sodium channel blocker, did not produce significant neuroprotective effect.

• The Korean Journal of Pain
• /
• 제12권1호
• /
• pp.119-122
• /
• 1999

Glossopharyngeal neuralgia is a rare syndrome that involves episodic bursts of pain in the sensory distributuion of the ninth cranial nerve. The nature of the pain is characterized by excruciating shock-like pain in the region of the tonsillar fossa or pharynx and can radiate to the ear or the angle of the jaw. Like trigeminal neuralgia, glossopharyngeal neuralgia typically responds to anticonvulsant agents such as carbamazepine. However, dose of carbamazepine needs to be increased gradually to avoid side effects. If the patient can not tolerate until effective carbamazepine level is reached, phenytoin can be administered intravenously at the same time that oral carbamazepine therapy is begun. We present fifty-three year old female patient suffering from glossopharyngeal neuralgia who did not respond to initial carbamazepine therapy, but responded to concomitant intravenous infusion of phenytoin.

• 대한한방내과학회지
• /
• 제24권2_4호
• /
• pp.1080-1086
• /
• 2003

As the use of anticonvulsant increases in neurologic field, more studies are needed to reveal various harmful effects of this medication. Especially as for carbamazepine, thrombocytopenia may appear during administration of the medication, regardless of dosage. We, the authors, report that we diagnosed the patient as Bigiheo and Eumheohyeolheo, who was suffering from insomnia, diarrhea, papura, and serious thrombocytopenia. We presumed that the symptoms could be induced by carbamazepine, and used Samulgwibitanggamibang to treat her and obtained positive results.

• 생물정신의학
• /
• 제5권2호
• /
• pp.283-287
• /
• 1998

The mother was 24 years old, primipara, and had been taking carbamazepine 400mg(serum concentration $5.0-8.5{\mu}g/ml$) during pregnancy without any clinical seizures. A male baby with physical malformation was delivered on week 39. The malformation is extradigit(polydactily) on X-ray of right foot and left mild hydronephrosis on ultrasonography and renal scan with radioactive material. We reported this rare case and reviewed related articles about teratogenic effect of carbamazepine, mechanism of action and prevention of teratogenesis.

• 생물정신의학
• /
• 제5권2호
• /
• pp.227-234
• /
• 1998

Objective : Many evidences suggest that patients with bipolar disorder have functional abnormalities in their postreceptor signal transduction pathways, and mood stabilizing effect of lithium is exerted by modulating this dysfunctioning system. Carbamazepine, an antiepileptic agent, is also known to be effective in the treatment and prevention of bipolar disorder. But the precise mechanism of action of the drug is still poorly understood. This study was performed to elucidate the possible therapeutic mechanism of carbamazepine. Method : The effects of chronic carbamazepine administration on protein kinase A and protein kinase C activities in frontal cortex of rat brain after 2 weeks of drug administration were measured and compared with those of control subjects. Results : Mean(${\pm}SE$) value of activity(phosphate transfer ${\mu}mol/mg$ of $protein{\cdot}min$) of protein kinase A in control and test group was $0.249563{\pm}0.036$ and $0.539853{\pm}0.078$, and that of protein kinase C was $0.654817{\pm}0.053$ and $1.146205{\pm}0.052$ respectively, being increased in test group. And differences between the two groups were statistically significant for both enzymes(protein kinase A ; p<0.01, protein kinase C ; p<0.001). Conclusion : These results show that chronic carbamazepine administration increases protein kinase A and C activities, and concerning the possible mode of therapeutic action in bipolar disorder it is suggested that enhanced enzymes phosphorylate receptor-G-protein-effector complexes to dampen hyperfunctioning neuronal activity and thus stabilize the system.

• 한국임상약학회지
• /
• 제6권2호
• /
• pp.19-23
• /
• 1996

Carbamazepine is an anticonvulsant drug that has been shown to be as effective as phenytoin or phenobarbital in treatment of grand mal and complex partial seizures and is also approved as the drug of choice for treatment of the pain associated with trigerminal neuralgia. And the therapeutic or toxic effects of carbamazepine are better related to plasma concentration than to dosage, which can be attributed to interindividual variability in the pharmacokinetics. A slow rate of carbamazepine dissolution in the gastrointestinal tract is believed to be the cause of its relatively slow and erratic rate of absorption. For these reasons pharmacokinetic evaluation of newly formulated carbamazepine is neccessary. In this study, the bioequivalence in carbamazepine between the $TegretoI^{TM}$ CR tablet (Geigy Co.) and $Carmazepine^{TM}$ CR tablet (Myung In Co.) was evaluated. 12 normal volunteers (age $21\~27$ years old) was divided into two groups, and a randomized cross-over study was employed. The pharmacokinetic parameters ($C_{max},\;T_{max}$ and AUC) obtained of oral administration of each formulatim of carbamazepine 400 mg were evaluated and ANOVA was utilized for the statistical analysis of parameters. $C_{max}\;is\;8.26{\pm}3.1{\mu}g/ml\;(C.V.\;37.3\%)\;in\;TegretoI^{TM}\;and\;9.39\{pm}2.9{\mu}g/ml\;(C.V.\;30.5\%)$ in $Carmazepine^{TM},\;T_{max}\;is\;28.0{\pm}5.9\;hrs(C.V.\;21.1\%)$ in $Tegretol^{TM}\;and\;24.0{\pm}7.2\;hrs(C.V.\;30.2\%)$ in $Carmazepine^{TM}$ and AUC is $786.4{\pm}360.5{\mu}g{\cdot}hr/ml\;(C.V.\;45.8\%)$ in $TegretoI^{TM}\;and\;792.8{\pm}228.6{\mu}g{\cdot}hr/ml\;(C.V.\;28.8\%)$ in $Carmazepine^{TM}$, respectively. As the result of the data, two formulations are bioequvalent, and the lower C.V. of $Carmazepine^{TM}$ in every individual can be merit.

• 대한임상약리학회:학술대회논문집
• /
• 대한임상약리학회 1995년도 정기총회 및 추계학술대회
• /
• pp.49-49
• /
• 1995